The FDA has accepted the supplemental new drug application for decitabine/cedazuridine plus venetoclax to treat adults with AML.

The Trump administration's recent travel and visa restrictions are preventing medical residents from starting their jobs in the US.

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

The FDA has published more than 200 complete response letters, sent as replies for applications submitted from 2020 to 2024.

This article was originally published on Stateline. The giant tax and spending bill President Donald Trump signed into law over the weekend includes the biggest health care spending cuts in U.S.

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited cont ...

Mass firings and grant terminations have disrupted research and other operations at the National Cancer Institute.

The composition of the gut microbiome appears to be associated with treatment response in patients with pancreatic cancer, research suggests.

Uterine cancer cases and deaths are projected to increase in Black women and White women in the United States.

Breast cancer patients may have inferior recurrence-free survival after neoadjuvant chemotherapy if they are overweight or obese at diagnosis.

We report, for the first time to the best of our knowledge, the largest cohort of serial hs-TnI surveillance in patients diagnosed with cancer and treated with ICIs therapies,” the researchers wrote.